We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Research in ALS Study (CRiALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00136500
Recruitment Status : Recruiting
First Posted : August 29, 2005
Last Update Posted : November 20, 2017
Information provided by (Responsible Party):

August 25, 2005
August 29, 2005
November 20, 2017
February 2005
December 2027   (Final data collection date for primary outcome measure)
Recruitment [ Time Frame: Annually ]
Since this is an umbrella/gateway protocol through which individuals are recruited to participate in a range of studies, outcome is assessed in terms of recruitment.
Not Provided
Complete list of historical versions of study NCT00136500 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Clinical Research in ALS Study
Clinical Research in Amyotrophic Lateral Sclerosis
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).
Research goals include elucidation of the complex relationship between ALS and related neurodegenerative disorders, development of both wet and dry biomarkers of disease, and delineation of the full course of the natural history of disease from the early pre-symptomatic stages through established and even late-stage disease. These goals are accomplished through the recruitment and evaluation of patients with ALS and related diseases, family members (including people at genetic risk for ALS, but who are not yet affected), and healthy controls.
Observational Model: Other
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
DNA, blood, urine, CSF, skin biopsies
Non-Probability Sample

The CRiALS research program aims to recruit three types of participants:

  • Individuals affected with ALS or a related neurodegenerative disease
  • Unaffected individuals from pedigrees in which the genetic cause of ALS is known
  • Healthy controls
Amyotrophic Lateral Sclerosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2027
December 2027   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. At least 18 years of age.
  2. Member of at least one of the following categories:

    1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial)
    2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases.
    3. Healthy controls
  3. Able and willing to comply with relevant procedures.

Exclusion Criteria:

Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Eliana Reyes 888-413-9315 fals@med.miami.edu
Contact: Danielle Dauphin 888-413-9315 fals@med.miami.edu
United States
FALS feasibility
Not Provided
Not Provided
Michael Benatar, University of Miami
Michael Benatar
  • ALS Association
  • ALS Recovery Fund
Principal Investigator: Michael Benatar, MD, PhD. University of Miami
University of Miami
November 2017